Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A synthetic or recombinant construct composed of multiple immunogenic peptide sequences (epitopes) derived from Plasmodium falciparum pre-erythrocytic antigens (CSP, LSA1, LSA3, LSAP2, ETRAMP5). Designed to induce broad and robust immune responses, targeting several key antigens simultaneously to improve vaccine efficacy against malaria by eliciting CD8+ T cells, CD4+ T cells, and neutralizing antibodies.
Elicits humoral and cellular immune responses against multiple pre-erythrocytic antigens of Plasmodium falciparum, preventing liver stage infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multi-Epitope String from Plasmodium falciparum Pre-Erythrocytic Antigens.